On the use of population-based registries in the clinical validation of genetic tests for disease susceptibility

Genetics in Medicine

Volumn 2, Issue 3, 2000, Pages 186-192

  Yang, Quanhe ^a   Khoury, Muin J ^a   Coughlin, Steven S ^b   Sun, Fengzhu ^c   Flanders, W Dana ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Case control study; Epidemiologic methods; Genetic testing; Registries

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER REGISTRY; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; FEMALE; GENETIC RISK; GENETIC SCREENING; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEURAL TUBE DEFECT; POPULATION RESEARCH; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; VALIDATION PROCESS;

EID: 0034535334     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/00125817-200005000-00005     Document Type: Article

References (55)

1. Genetic testing for cancer risk
2. A collaborative survey of 80 mutations in the BRCA1/BRCA2 breast and ovarian cancer susceptibility gene: Implications for presymptomatic testing and screening
3. BRCA genes-booking, fortune telling and medical care
4. The clinical introduction of genetic testing for Alzheimer diseases: An ethical perspective
5. Alzheimer disease research comes of age: The pace accelerates
6. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
7. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus
8. Predictive genetic testing: From basic research to clinical practice
9. What do we mean by genetic testing?
10. The new genetics: Genetic testing and public health
11. Epidemiologic evaluation of screening for risk factors: Application to genetic screening
12. Congenital malformation surveillance: Two American systems
13. The Danish Cancer Registry: History, content, quality and use
14. Surveillance
15. The future of genetic studies of complex human diseases: An epidemiologic perspective
16. Estimating exposure-specific disease rates from case-control studies using Bayes theorem
17. Multivariate estimation of exposure-specific incidence from case-control studies
18. The occurrence of lung cancer in man
19. Use and misuse of population attributable fraction
20. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida
21. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects
22. 5,10 methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects
23. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida
24. MTHFR and birth defects
25. Prevalence and contribution of BRCA1/BRCA2 mutation in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer
26. Pathology of familial breast cancer: Differences between breast cancer in carriers of BRCA1 or BRCA2 mutations and sporadic cases
27. Genetic analysis of breast cancer in the cancer and steroid hormone study
28. Estimates of the gene frequency of BRCA1/BRCA2 and its contribution to breast and ovarian cancer incidence
29. The future of genetic studies of complex human diseases
30. Geographic patterns of childhood insulin-dependent diabetes mellitus
31. Geographic differences in the risk of insulin-dependent diabetes mellitus: The importance of registries
32. Surveillance for stroke in Canada
33. Public health surveillance: Historical origins, methods and evaluation
34. The lifetime risk of developing breast cancer
35. Multivariate estimation of exposure-specific incidence from case-control studies
36. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
37. A comparison of three approaches to estimate exposure-specific incidence rates from population-based case-control data
38. Assessing individual risk for breast cancer: Risky business
39. The new genetics: Implications for clinical services in Britain and the United States
40. The new genetics: Psychological responses to genetic testing
41. Genetic testing, common diseases, and health service provision
42. The new genetics: The new genetics in clinical practice
43. Genetic testing for cancer risk
44. Ethics and genetic testing
45. Code of practice and guidance on human genetic testing services supplied direct to the public: Advisory Committee on Genetic Testing
46. The past as prologue: Race, class, and gene discrimination